Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660436 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
NCT03660436: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03660436 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 131 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (118% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03660436, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effects of experimental medication BMS-986165 in healthy male participants.
Interventions
- DRUG BMS-986165
- DRUG MMF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 1 |
What the finished NCT03660436 record still lists
NCT03660436 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (118% higher).
The record links to 0 conditions, and to 2 interventions - of which BMS-986165 is the first listed.
NCT03660436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03660436 about?
NCT03660436 is a clinical study titled "An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants". The purpose of this study is to investigate the effects of experimental medication BMS-986165 in healthy male participants.
What is the current status of trial NCT03660436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2018-08-14. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT03660436?
The interventions under investigation include: BMS-986165 (DRUG), MMF (DRUG).
Who is sponsoring clinical trial NCT03660436?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03660436's enrollment target sits among peer trials
131 439th of 2000 higher than 1,562 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI